On November 2, 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") reported that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ("FDA") for leuprolide acetate for injection (Press release, Amneal Pharmaceuticals, NOV 2, 2022, View Source [SID1234622831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Harsher Singh, SVP for Amneal Biosciences, stated, "We are making tremendous progress expanding our injectables business. This latest new product is another key therapeutic for the institutional market and another complex, high value launch by the team."

Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. For full prescribing information, see package insert located here.

According to IQVIA, U.S. annual sales for this product for the 12 months ended September 2022 were $81 million.